Tango Therapeutics, Inc. (TNGX): Entry into a Material Definitive Agreement
Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d81492dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version TANGO THERAPEUTICS, INC. (a Delaware corporation) 18,166,667 Shares of Common Stock And Pre-Funded Warrants to Purchase 1,833,395 of Common Stock UNDERWRITING AGREEMENT June 9, 2026 J.P. Morgan Securities LLC Le
How this was made
The 30-second read
Why it matters
This is a primary-source disclosure of a new equity offering mechanism (common shares plus pre-funded warrants), which can change dilution expectations and financing runway assumptions.
Market read
Traders can treat this as a fresh capital-raise catalyst for TNGX, with dilution/financing-runway implications.
What to watch
Final prospectus terms (offering price, warrant strike, use of proceeds) are not in the excerpt; those details often drive the actual magnitude of price reaction.
Background
The article is an SEC 8-K Item 1.01 describing entry into an underwriting agreement tied to an automatic shelf registration statement.
Ticker impact
Tango Therapeutics entered a material definitive underwriting agreement for an offering of 18,166,667 common shares plus pre-funded warrants.
Near-term downside/volatility risk from dilution overhang; direction depends on pricing/size details not included here.
An 8-K underwriting agreement is a primary disclosure of a capital raise, typically increasing dilution expectations even without the final pricing terms in the excerpt.
Market effects
Adds to the ongoing small-cap biotech financing backdrop; may reinforce investor preference for balance-sheet clarity.
US small-cap biotech tape; potential spillover to similarly capital-constrained peers.
Limited direct global impact; primarily affects US-listed biotech risk appetite.
Counterpoint
If the raise funds near-term clinical/operational milestones, the dilution overhang could be temporary and the market may refocus on runway extension.
Key entities
- issuerTango Therapeutics, Inc.
Company entering the underwriting agreement for a common stock and pre-funded warrant offering.
- underwriterJ.P. Morgan Securities LLC
Representative underwriter in the underwriting agreement.
- underwriterLeerink Partners LLC
Representative underwriter in the underwriting agreement.
